Patterns of Cancer Genetic Testing: A Randomized Survey of Oregon Clinicians

Table 4

Reasons why clinicians did not order or recommend various cancer genomic tests among clinicians who do not order that specific test.

	Not familiar with test; 𝑛 (%)^a; (95%  CI)^b	Clinical outcomes would not change; 𝑛 (%)^a; (95%  CI)^b	Costs too much/insurance will not cover it; 𝑛 (%)^a; (95%  CI)^b	Test not valid; 𝑛 (%)^a; (95%  CI)^b	Practice guidelines do not include this test; 𝑛 (%)^a; (95%  CI)^b	Test not relevant; to patients; 𝑛 (%)^a; (95%  CI)^b
OncoVue^c,d	787 (79.0%)	24 (2.4%)	106 (10.6%)	11 (1.1%)	173 (17.4%)	75 (7.5%)
	(76.45%–81.4%)	(1.6%–3.6%)	(8.9%–12.7%)	(0.6%–2.0%)	(15.1%–19.9%)	(6.1%–9.3%)
Fecal DNA^e	783 (71.8%)	37 (3.4%)	119 (10.9%)	47 (4.3%)	216 (19.8%)	57 (5.3%)
	(69.1%–74.4%)	(2.5%–4.7%)	(9.2%–12.9%)	(3.3%– 5.7%)	(17.6%–22.3%)	(4.1%–6.7%)
Tumor gene; expression; profiles^f,g	126 (50.6%)	14 (5.6%)	21 (8.4%)	6 (2.4%)	17 (6.8%)	21 (8.4%)
	(44.4%–56.8%)	(3.3%–9.3%)	(5.6%–12.6%)	(1.1%–5.3%)	(4.3%–10.7%)	(5.5%–12.6%)
CYP2D6 g	131 (42.1%)	10 (3.2%)	10 (3.2%)	4 (1.3%)	19 (6.1%)	96 (30.9%)
	(36.7%–47.7%)	(1.7%–5.9%)	(1.7%–5.9%)	(0.5%–3.4%)	(3.9%–9.4%)	(26.0%–36.3)^h
UGT1A1 i	187 (58.4%)	NA^j	7 (2.2%)	NA^j	16 (5.0%)	126 (39.4%)
	(52.9%–63.7%)		(1.0%–4.5%)		(3.1%–8.0%)	(34.1%–44.9%)^k
KRAS i	108 (40.3%)	NA^j	4 (1.5%)	NA^j	9 (3.4%)	127 (47.4%)
	(34.6%–46.3%)		(0.6%–3.9%)		(1.7%–6.4%)	(41.4%–53.4%)^l

^aThe column % reflects the percent responding within each practice category.
^bCI: confidence interval.
^cOncoVue is a multigene screening panel for patients without breast cancer.
^dAmong clinicians who recommend breast and ovarian screening to patients without breast cancer.
^eAmong clinicians who recommend colorectal cancer screening to patients without colorectal cancer.
^fBreast cancer tumor gene expression profiles include Oncotype DX, MammaPrint, and H/I ratio.
^gAmong clinicians who treat patients for breast cancer.
^hTest not relevant to patients because clinician does not prescribe tamoxifen to patients.
ⁱAmong clinicians who treat patients for colorectal cancer.
^jUnable to report estimates due to small cell size.
^kTest not relevant to patients because clinician does not prescribe irinotecan to patients.
^lTest not relevant to patients because clinician does not prescribe anti-EGFR therapy to patients.